Clin Asst Prof Lee Jie Xin Joycelyn

Dr Lee is a medical oncologist in the Department of Gastrointestinal Oncology, Division of Medical Oncology at National Cancer Centre Singapore. She sees patients and conducts clinical research in the field of gastrointestinal oncology, with an interest in hepatopancreatobiliary cancers, immuno-oncology and supportive care. She participates in postgraduate and undergraduate medical teaching.

• FAMS (Medical Oncology) 2017
• MRCP (UK) 2013
• M.Med (Int Med) 2013
• MBBS (Singapore) 2011

• SSO-CIC Executive Committee 2021 – present
• Member of SSO, ASCO, ESMO since 2014

• SingHealth Quality Service Award 2018, 2019
• Young Educator Award 2012

• Hepatopancreatobiliary cancers
• Immuno-oncology
• Supportive care

• Immuno-Oncology Toxicity Database (Principal Investigator)

• Radioembolisation with Y90-resin microspheres followed by nivolumab for  advanced hepatocellular carcinoma (CA 209-678): a single-arm single-centre phase 2 trial. Tai D, Loke K .. Lee J .. Choo SP. Lancet Gastro Hepatol 2021 Dec; 6(12): 1025 – 1035.
• Impact of immune-related adverse events on efficacy of Immune Checkpoint Inhibitors in patients with advanced hepatocellular carcinoma. Ng KYY, Tan SH .. Lee JJX. Liver Cancer 2021.
• Locoregional therapy in hepatocellular carcinoma: when to start, when to stop and when to revisit. Lee JJX, Tai D, Choo SP. ESMO Open 2021 June; 6(3):100.129
• Clinical outcomes with Multikinase inhibitors after Progression on First-line Atezolizumab plus Bevacizumab in Patients with advanced HCC: a Multinational, Multicentre Retrospective study. Yoo C, Kim JH .. Lee J.. et al. Liver Cancer 2021 Apr; 10(2): 107 - 114